India, Oct. 7 -- Biocon announced on Tuesday that its subsidiary, in partnership with Carnegie Pharmaceuticals LLC, has received tentative approval from the US Food and Drug Administration (USFDA) for its Rifaximin Tablets, 550 mg under an Abbreviated New Drug Application (ANDA).
The medication is indicated for reducing the risk of overt hepatic encephalopathy (HE) recurrence and for the treatment of irritable bowel syndrome with diarrhoea (IBS-D) in adults, the company said in a regulatory filing.
Published by HT Digital Content Services with permission from Dion Global Solutions Limited....